Welcome back to the journal review. This month we're working through the November 2026 issue of Dermatologic Surgery, and I've pulled four pieces worth your time — a case report on an incidental breast cancer recurrence caught during Mohs, a retrospective series on squamoid eccrine ductal carcinoma, a quick practical technique piece on preventing sharps injuries, and a case report on surgical correction of severe rhinophyma. Let's get into it. First up is a case report titled "Expect the Unexpected: Discovering Breast Cancer Recurrence Upon Histopathologic Analysis During Mohs Micrographic Surgery." The setup here is one every Mohs surgeon half-expects but rarely plans for — the incidental noncutaneous finding on a frozen section. The authors note there's very little data on how often this happens, though we do know incidental skin cancers themselves turn up in something like one in twenty Mohs cases, and those incidental finds can sometimes be more aggressive than the index tumor. For comparison, incidental cancers found on permanent sections after wide local excision for melanoma run around two percent. And patients with a history of therapeutic radiation carry a meaningfully increased risk of subsequent skin cancers — on the order of a quarter higher risk — sometimes even outside the radiation field itself. The case: a woman in her early sixties with a remote history of DCIS — ductal carcinoma in situ — of the left breast, treated fourteen years earlier with partial mastectomy, whole breast radiation, and five years of tamoxifen, presented for Mohs surgery of a superficial BCC located right on the nipple-areolar complex, near her old mastectomy scar. During stage one frozen section processing, the pathology showed the expected residual basal cell carcinoma, but also atypical ductal structures with central comedo necrosis — morphology concerning for recurrent DCIS rather than anything related to the skin cancer she was there for. The surgeons did exactly what you'd want: they stopped the Mohs procedure, closed temporarily, and sent tissue for permanent sections rather than trying to adjudicate this on frozen tissue. Permanent sections confirmed both the basal cell carcinoma and intermediate-grade DCIS colonizing the lactiferous ducts in the dermis, with intact myoepithelial cells arguing against invasion — though the authors note the tissue available was limited, which capped how much further ancillary staining could be done at that point. She was referred to surgical oncology, underwent partial mastectomy revealing four millimeters of residual grade two, ER and PR positive DCIS with positive posterior margins, needed a second partial mastectomy to get clear margins, and based on the proximity to her original scar and matching grade and receptor status, this was adjudicated as recurrent disease rather than a new primary. She's now on anastrozole with quarterly surveillance mammography and remains in remission. There's no methods or statistics section here — this is a case report, so the value is entirely in the teaching point. The authors found only one other reported case of breast carcinoma turning up as a collision tumor during Mohs, that one being metastatic disease discovered during Mohs for a scalp squamous cell carcinoma. The practical message for us: patients with a prior cancer history and prior radiation exposure are a population where atypical or unexpectedly aggressive histology deserves a second look, and when something looks ductal rather than keratinocytic on a frozen section, the right move is exactly what happened here — pause, close temporarily, and get permanent sections with the full complement of ancillary studies, including ER, PR, and HER2, rather than trying to force a diagnosis intraoperatively. This isn't practice-changing in the sense of altering how you do Mohs day to day, but it's a very good reminder to keep a low threshold for deferring to permanent sections when frozen histology surprises you, particularly in irradiated skin. Next, a retrospective review of squamoid eccrine ductal carcinoma, or SEDC, out of the Cleveland Clinic. This is a genuinely rare adnexal tumor — fewer than seventy-five cases exist in the entire literature, with the two largest prior series comprising only thirty and nineteen cases respectively. Everything else is single case reports, so there's no real consensus on workup or management, and that's the gap this paper is trying to fill with a modest single-institution series. Clinically, SEDC shows up in older patients as nondescript erythematous papules or plaques on sun-exposed skin, and the histology is the real pitfall here — a biphasic pattern where the superficial component looks just like ordinary squamous cell carcinoma, while deeper sections reveal infiltrative cords and ductal structures that only become apparent with adequate tissue depth. A superficial shave biopsy will frequently miss this and get called SCC. Methodologically, the authors pulled surgical pathology logs from 2001 to 2021, identified seventeen cases, excluded three treated elsewhere, and ended up with fourteen for analysis. There's no comparative statistical test here — no Cox model, no regression — this is purely a descriptive case series, which honestly is the right and really the only feasible design given how rare this tumor is. You simply cannot run a prospective comparative trial on a tumor with fewer than a hundred reported cases worldwide; a retrospective chart pull across two decades is how you generate any signal at all. The results: seven men, seven women, average age at diagnosis seventy-one, with a fairly short average follow-up of seventeen months. Three patients recurred, two of whom died, and a separate patient died of metastatic disease after surgery — so three deaths total in this cohort of fourteen, which is a sobering number even accounting for the small sample. Intraoperative diagnosis changed in six of the fourteen cases — mostly initially read as squamous cell carcinoma until a debulk specimen sent for permanent sections confirmed SEDC. Eight of fourteen tumors were two centimeters or larger at presentation. Perineural invasion showed up in five of fourteen, and both disease-specific deaths occurred in patients with tumors six centimeters or larger. Eleven patients were treated with standard Mohs, two with "slow" Mohs using permanent sections, and one with wide local excision. Here's the finding that should stick with you: all three recurrences occurred in Mohs-treated patients despite clear margins — two in the slow-Mohs group and one in standard Mohs. The authors float a few explanations: false-negative slide interpretation, inherently aggressive tumor biology, and high-risk features like immunosuppression and perineural invasion clustering in the same patients. Speaking of which, ten of the fourteen patients were immunosuppressed — five solid organ transplant recipients, four with chronic lymphocytic leukemia, one on chronic steroids — and notably, every single patient who recurred was immunosuppressed, and four of the five perineural invasion cases occurred in this immunosuppressed subgroup. The honest limitations here are what you'd expect from a rare-tumor retrospective series: only fourteen patients, a single institution, and a median follow-up of under a year and a half, which is genuinely too short to make confident statements about long-term recurrence risk for a tumor that can clearly recur even after histologically clear margins. The authors are appropriately modest in their conclusions rather than overreaching. Practically, this is useful but not practice-changing in a dramatic sense — more a sharpening of clinical suspicion. If you're looking at an elderly patient with a nondescript plaque on sun-exposed skin and the biopsy reads as SCC, a punch rather than a superficial shave may be worth considering if the clinical gestalt doesn't fit, specifically to capture the deeper ductal component that distinguishes SEDC. And the recurrence-despite-clear-margins finding is the real takeaway for your own patients with this diagnosis — particularly immunosuppressed patients or those with perineural invasion on the specimen — these patients need genuinely long-term surveillance, not the routine post-op check, because clear Mohs margins did not reliably predict cure in this series. Third, a short technique piece: "Streamlining Surgical Trays: An Approach to Prevent Sharps Injuries in Dermatologic Surgery." This one's purely practical, no results or statistics to walk through — just a workflow solution to a documented problem. The authors cite a 2023 survey of American College of Mohs Surgery members showing that well over half of respondents had at least one sharps injury in the past year, the large majority of those being self-inflicted suture needlesticks, with a meaningful fraction — about one in seven — resulting in bloodborne pathogen exposure, and nearly half going unreported entirely. A separate survey found the leading reasons cited were feeling rushed and awkward posture — in other words, workflow and field organization problems, not technique failures per se. Their fix is refreshingly low-tech: three items on the tray. A tilted medicine cup, stabilized on a folded towel for friction, serves as the designated parking spot for actively used sharps like the scalpel, with instruments laid on their side to protect blade edges and reduce dulling. A one-inch square of foam at the top of the tray becomes the consolidated landing zone for disposable sharps — used needles, used blades. And a clip-style scalpel blade remover at the bottom of the tray allows blade removal without resorting to hemostats or needle drivers, which both reduces injury risk during that specific maneuver and spares your more expensive instruments from damage. The whole system is strikingly cheap — the foam alone runs about five cents per tray — and both the cup and blade remover are autoclavable and reusable. Over two years of use in their multispecialty Mohs practice, they report zero sharps injuries. To be clear about the evidentiary weight here: this is a single practice's uncontrolled before-and-after observation, not a trial, and the authors frame it accordingly — as a practical safety solution rather than a formally validated intervention. But the underlying problem it addresses is well documented and underreported, and the solution costs essentially nothing and requires no new equipment or training beyond habit formation. This is about as close to a free, zero-downside practice tweak as you'll find in the literature — worth adopting in your own suite regardless of the modest evidence base. Last, a case report: "The Pendulous Nose Correction: Rhinophyma's Unique Facade." This is a presentation-and-management piece rather than a comparative study, so I'll walk it through as the case unfolds. Rhinophyma, for context, is the end-stage phymatous variant of rosacea — fibrosis, vascular proliferation, and sebaceous hyperplasia progressively deforming the nose, classically in longstanding untreated rosacea in middle-aged to older men. The patient was a man in his fifties with six years of progressive, severely disfiguring nasal enlargement that had actually been evolving since adolescence, starting as redness and mild swelling. By presentation it had become socially and functionally disabling — he described withdrawal from social interaction and lost job opportunities — plus significantly impaired nasal breathing from the bulk of tissue. On exam he had an enlarged, irregularly lobulated, bulbous nose with a genuinely pendulous growth of the nasal tip, thickened skin, and sebaceous hyperplasia distorting every aesthetic subunit of the nose. Management was surgical debulking under local anesthesia using a monopolar radiofrequency electrosurgical device with an eight-millimeter loop in cut-coagulate mode, power titrated between twenty-five and thirty watts depending on tissue resistance and the depth of sculpting needed at each point. He improved substantially within a week, developed a mild pustular discharge managed with a short course of oral ciprofloxacin, and achieved immediate restoration of normal nasal architecture with durable improvement in both breathing and quality of life. The discussion situates this within the broader phyma family — blepharophyma, otophyma, metophyma, gnatophyma, with the nose being by far the most common site — and reviews the standard management toolkit: medical therapy for the underlying rosacea, plus surgical modalities including CO2, KTP, pulsed dye, and Nd:YAG laser resurfacing, intense pulsed light, radiofrequency ablation, dermabrasion, or excision, chosen based on severity and available equipment. There's no comparative data here — this is one case demonstrating that RF debulking is an effective, accessible option for a severe, bulky presentation — but the teaching point is a reasonable one: early intervention in phymatous rosacea limits both the cosmetic and functional progression, and even in advanced, pendulous disease like this, radiofrequency debulking can achieve single-session, immediate architectural restoration without more elaborate reconstructive planning. That wraps our four articles for this issue. The through-line this month, if there is one, is really about vigilance and workflow — staying alert to the unexpected on frozen section, respecting how often rare adnexal tumors get misread on superficial biopsy, tightening up something as mundane as tray organization, and recognizing how much a single well-chosen energy-based debulking session can do for severe phymatous disease. Thanks for listening, and I'll see you next month.